Cholesterol Metabolism as a Potential Therapeutic Target and a Prognostic Biomarker for Cancer Immunotherapy
Huixian Zhang,Wencheng Zhao,Xingya Li,Yayi He
DOI: https://doi.org/10.2147/OTT.S315998
IF: 4
2021-06-21
OncoTargets and Therapy
Abstract:Huixian Zhang, 1– 3 Wencheng Zhao, 1, 2 Xingya Li, 3 Yayi He 1, 2 1 Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, Shanghai, 200433, People's Republic of China; 2 Tongji University, Shanghai, 200433, People's Republic of China; 3 Department of Medical Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou City, Henan Province, 450052, People's Republic of China Correspondence: Yayi He Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, Shanghai, 200433, People's Republic of China Tel +86-13818828623 Email Xingya Li Department of Medical Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou City, Henan Province, 450052 Tel +86-13838253946 Email Checkpoint-based immunotherapies, such as programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1) inhibitors, have shown promising clinical outcomes in many types of cancers. Unfortunately, the response rate of immune checkpoint inhibitors is low. It is very important to discover novel therapeutic targets and prognostic biomarkers. Cholesterol metabolism has been demonstrated to be related to the occurrence and development of a variety of tumors and may provide a new breakthrough in the development of immunotherapy. First of all, cholesterol metabolism in the tumor microenvironment affects the function of tumor-infiltrating immune cells. In addition, intracellular cholesterol homeostasis is an important regulator of immune cell function. Furthermore, drugs that act on cholesterol metabolism affect the efficacy of immunotherapy. What is more, peripheral blood cholesterol level can be a biomarker to predict the efficacy of immunotherapy. In this review, we aimed to explore the potential role of cholesterol metabolism on immunotherapy. By summarizing the major findings of recent preclinical and clinical studies on cholesterol metabolism in immunotherapy, we suggested that cholesterol metabolism could be a potential therapeutic target and a prognostic biomarker for immunotherapy. Keywords: cholesterol metabolism, immunotherapy, immune cell, therapeutic target, biomarker Immunotherapy for tumors, which has recently achieved clinical success, is revolutionizing cancer treatment. 1 Checkpoint-based immunotherapies are agents that target the inhibitory receptors expressed on activated T cells. 2–4 Immune checkpoint inhibitors (ICIs) take effect by overcoming or alleviating tumor-induced immunosuppression, thereby releasing inhibitory T-cell-mediated antitumor responses. 5 , 6 Programmed death-1 (PD-1)/programmed death ligand-1 (PD-L1) inhibitors have been approved as a systematic treatment for various types of cancers, such as melanoma, non-small cell lung cancer (NSCLC), hepatocellular carcinoma, renal cell carcinoma and so on. 7–10 Although immunotherapy has shown the application potential in a variety of malignancies, a relatively small proportion of patients have so far benefited from ICIs. 11 , 12 Thus, the discovery of more effective immunotherapy targets and the identification of predictive biomarkers for immunotherapy become urgently warranted. Cholesterol, a subtype of lipids, plays an important role in cell homeostasis, from the basic components that maintain the integrity and stability of cell membranes to the precursors of different forms of important sterols such as vitamins and hormones. 13 , 14 Both clinical and experimental studies support the link between changes in cholesterol metabolism and cancer development. 15–17 On the one hand, elevated serum cholesterol levels have been reported to increase the incidence rate of colorectal, prostate and other cancers. 18 Considering the concomitant relationship between obesity and hyperlipidemia, a prospective study investigating the association between prediagnosis blood lipid concentrations and breast cancer risk reported that serum cholesterol levels did correlate with breast cancer risk regardless of BMI. 19 On the other hand, accumulated reports have shown that cholesterol can suppress immune cells, regulate cell survival and modulate cancer stem cells. 20 , 21 By summar -Abstract Truncated-
oncology,biotechnology & applied microbiology